Abstract:Antibodies, particularly of the immunoglobulin G (IgG) isotype, are a group of biomolecules that are extensively used as affinity reagents for many applications in research, disease diagnostics, and therapy. Most of these applications require antibodies to be modified with specific functional moieties, including fluorophores, drugs, and proteins. Thus, a variety of methodologies have been developed for the covalent labeling of antibodies. The most common methods stably attach functional molecules to lysine or cysteine residues, which unavoidably results in heterogeneous products that cannot be further purified. In an effort to prepare homogeneous antibody conjugates, bioorthogonal handles have been site-specifically introduced via enzymatic treatment, genetic code expansion, or genetically encoded tagging, followed by functionalization using bioorthogonal conjugation reactions. The resulting homogeneous products have proven superior to their heterogeneous counterparts for both in vitro and in vivo usage. Nevertheless, additional chemical treatment or protein engineering of antibodies is required for incorporation of the bioorthogonal handles, processes that often affect antibody folding, stability, and/or production yield and cost. Accordingly, concurrent with advances in the fields of bioorthogonal chemistry and protein engineering, there is growing interest in site-specifically labeling native (nonengineered) antibodies without chemical or enzymatic treatments. In this review, we highlight recent strategies for producing site-specific native antibody conjugates and provide a comprehensive summary of the merits and disadvantages of these strategies.This article has not yet been cited by other publications.

Chemical Biology Approaches toward Precise Structure Control of IgG-Based Antibody-Oligonucleotide Conjugates.

A Versatile Chemo-Enzymatic Conjugation Approach Yields Homogeneous and Highly Potent Antibody-Drug Conjugates.

Antibody Drug Conjugates: Design and Selection of Linker, Payload and Conjugation Chemistry

Structure-Activity Relationship of Antibody-Oligonucleotide Conjugates: Evaluating Bioconjugation Strategies for Antibody-siRNA Conjugates for Drug Development

Site-Specific Antibody–Drug Conjugates: The Nexus of Bioorthogonal Chemistry, Protein Engineering, and Drug Development

Protocol to generate, purify, and analyze antibody-oligonucleotide conjugates from off-the-shelf antibodies

Precision Modification of Native Antibodies

Chemical technology principles for selective bioconjugation of proteins and antibodies.

Non-specific interactions of antibody-oligonucleotide conjugates with living cells

Bioanalytical approaches to support the development of antibody-oligonucleotide conjugate (AOC) therapeutic proteins

Overcoming limitations and advancing the therapeutic potential of antibody-oligonucleotide conjugates (AOCs): Current status and future perspectives

Antibody-Drug Conjugates: Design, Formulation and Physicochemical Stability

Recent preclinical and clinical advances in oligonucleotide conjugates

Self‐Assembled L–DNA Linkers for Rapid Construction of Multi‐Specific Antibody‐Drug Conjugates Library

Antibody Conjugates-Recent Advances and Future Innovations

Nickel-Catalyzed Antibody Bioconjugation

Linker and Conjugation Site Synergy in Antibody-Drug Conjugates: Impacts on Biological Activity

Antibody-drug conjugates: recent advances in conjugation and linker chemistries

Site-directed Conjugation of Single-Stranded DNA to Affinity Proteins: Quantifying the Importance of Conjugation Strategy

Precision Targeting in Oncology: the Future of Conjugated Drugs

The Dawn of a New Era: Targeting the "Undruggables" with Antibody-Based Therapeutics.